Abstract
ABATACEPT IN RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE. A MULTICENTRE STUDY OF 181 PATIENTS
Full text
Background: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA).
Objectives: Our aim was to assess the efficacy of abatacept (ABA) in RA patients with ILD.
Methods: Retrospective multicenter study of RA patients with ILD treated with ABA. ILD was diagnosed by HRCT. We have analyzed the following variables:
a)
1-point change the Modified Medical Research Council (MMRC);
b)
FVC improvement ≥10%; and improvement ≥10% in DLCO;
c)
radiological improvement in HRCT scan,
d)
changes in DAS28 score. Values were compared with baseline
e)
prednisone doses
Results: We studied 181 patients (94women/87 men) with ILD associated to RA. The follow-up was 12.1[6.2-24.1] months. The mean age was 64.54 ± 9.7 years. The median to progression of ILD was 12 [3-43.75] months. 81 patients were treated in monotherapy, 100 patients in combination therapy. The most frequent pattern was UIP 45,3%.
The most of patients who did not have dyspnea remained asymptomatic.
See results in
Figure1
. DAS28 also improved. We appreciate a decrease in the dose of prednisone compared to the initial dose.
Conclusion: ABA seems to be effective. However, should be verified in prospective and randomized studies.
Table 1
Disclosure of Interests: Carlos Fernández-Díaz Speakers bureau: Bristol-Myers, J. Loricera: None declared, Santos Castañeda Consultant for: Amgen, BMS, Pfizer, Lilly, MSD, Roche, Sanofi, UCB, A. Juan-Mas: None declared, Carmen Carrasco-Cubero: None declared, Ivette Casafont-Solé: None declared, RAQUEL ALMODOVAR: None declared, Noelia Alvarez-Rivas: None declared, CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco: None declared, Sergi Ordoñez : None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno : None declared, I. Hernández-Rodriguez: None declared, M. López-Corbeto: None declared, Maria Lopez Lasanta: None declared, Francisco Ortiz-Sanjuán: None declared, B. Alvarez-Rodríguez: None declared, A. Ruibal-Escribano: None declared, Rosa Expósito: None declared, M. Retuerto-Guerrero: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira: None declared, Natalia Mena-Vázquez: None declared, ANA URRUTICOECHEA-ARANA: None declared, C. Delgado-Beltran: None declared, José Luis Andréu Sánchez: None declared, Alejandro Olive: None declared, S, Rodriguéz-Muguruza: None declared, José Antonio Bernal-Vidal: None declared, E.C. Cervantes Pérez : None declared, Olga Maiz-Alonso Speakers bureau: Pfizer, R. Castellanos-Moreira: None declared, S Rodiguéz-Garcia: None declared, I. Cabezas-Rodriguez: None declared, Mireia Moreno : None declared, Ivan Castellví Consultant for: I received fees less than 5000USD as a consultant for Kern and Actelion, Paid instructor for: I received fees less than 2000USD as a instructor for Boehringer -Ingelheim, Novartis and Gebro, Speakers bureau: ND, Luis Marcelino Arboleya Rodríguez: None declared, C. González-Montagut Gómez: None declared, Blanca Garcia-Magallon: None declared, E. Salgado-Pérez: None declared, M. Rodíguez-Gómez: None declared, C. Fito-Manteca: None declared, J M Blanco: None declared, DESEADA PALMA SANCHEZ: None declared, Paloma Vela-Casasempere Grant/research support from: UCB, Abbvie, Pfizer, Roche, Bristol-Myer-Squibb (another research, not BIOBADASER related), Consultant for: UCB, Lilly, Pfizer, Roche, Bristol-Myer-Squibb, Speakers bureau: Roche, UCB, MSD, Pfizer, GSK, BMS, Lilly, Gemma Bonilla: None declared, R. López-Sánchez: None declared, J. Fernández-Melon: None declared, Cristina Hidalgo: None declared, Miguel A González-Gay Grant/research support from: Prof. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker’s bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Ricardo Blanco Grant/research support from: Abbvie, MSD, and Roche, Consultant for: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen
DOI: 10.1136/annrheumdis-2019-eular.6091Citation: Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1617Session: Rheumatoid arthritis - comorbidity and clinical aspects
(Scientific Abstracts)
45 organizations
Organization
H. VInalopo, Elche, SpainOrganization
H. Marqués de Valdecilla, Santander, SpainOrganization
H. Princesa, Madrid, SpainOrganization
H. Son Llàtzer., Palma de Mallorca, SpainOrganization
CHU Infanta Cristina, Badajoz, SpainOrganization
H. Fundación Alcorcon, Madrid, SpainOrganization
HULA, Lugo, SpainOrganization
H. Virgen del Rocio, Sevilla, SpainOrganization
H.Sierrallana, Torrelavega, SpainOrganization
H. Arnau de Vilanova, Lleida, SpainOrganization
H.de Pontevedra, Pontevedra, SpainOrganization
H.U. Virgen Macarena, Sevilla, SpainOrganization
H.Virgen De la Arrixaca, Murcia, SpainOrganization
Hospital Meixoeiro, Vigo, SpainOrganization
H.U. Vall d’Hebron, Barcelona, SpainOrganization
H. La Fe, Valencia, SpainOrganization
H. Txagorritxu, Vitoria, SpainOrganization
H. Laredo, Laredo, SpainOrganization
H. 12 De octubre, Madrid, SpainOrganization
H. León, León, SpainOrganization
H: Malaga, Malaga, SpainOrganization
H. Can Misses, Ibiza, SpainOrganization
H. Lozano Blesa, Zaragoza, SpainOrganization
H.Puerta Del hierro, Madrid, SpainOrganization
H. German Trias I Pujol, Badalona, SpainOrganization
H. Elda, Elda, SpainOrganization
H..Santiago de Compostela, Santiago, SpainOrganization
HU Donosita, Donostia, SpainOrganization
H. Clinic, Barcelona, SpainOrganization
H. Río Ortega, Valladolid, SpainOrganization
Parc Tauli, Barcelona, SpainOrganization
H. de la Santa Creu i Sant Pau, Barcelona, SpainOrganization
H.Central ASturias, Oviedo, SpainOrganization
H.Clinico, Valladolid, SpainOrganization
H. San Jorge, Huesca, SpainOrganization
CH Ourense, Ourense, SpainOrganization
H. Navarra, Pamplona, SpainOrganization
H. Basurto, Bilbao, SpainOrganization
H. Rafael Mendez, Lorca, SpainOrganization
HU Alicante, Alicante, SpainOrganization
H. La paz, Madrid, SpainOrganization
HU. Negrin, Gran Canaria, SpainOrganization
H. Son Espases, Palma de Mallorca, SpainOrganization
HU. Salamanca, Salamanca, Spain